https://charts.traderzeitung.de/phases/US20454B1044 string(1474) "{"isin":"US20454B1044","name":"Compass Therapeutics Inc","stock_id_xnas":20497319,"stock_id_xnys":null,"generated_at":"2026-09-14 06:52:00","days":[{"date":"2026-09-09","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":2.24,"close_at":"2026-09-09 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.195,"close_at":"2026-09-09 21:59:00","complete":true,"perf_pct":-2.0089},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":2.195,"close_at":"2026-09-09 22:00:00","complete":true,"perf_pct":0}]},{"date":"2026-09-10","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":2.18,"close_at":"2026-09-10 15:00:00","complete":true,"perf_pct":-0.6834},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.04,"close_at":"2026-09-10 21:59:00","complete":true,"perf_pct":-6.422},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":2.09,"close_at":"2026-09-11 00:34:00","complete":true,"perf_pct":2.451}]},{"date":"2026-09-11","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.995,"close_at":"2026-09-11 21:59:00","complete":true,"perf_pct":-4.5455},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Compass Therapeutics Aktie News & Nachrichten

[WKN: A2QF3P | Symbol: CMPX]

Realtimekurs

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.